Maternal antibody at delivery protects neonates from early onset group B streptococcal disease.

ABSTRACT:

Background

Further reduction in the group B streptococcal (GBS) disease burden in neonates in the United States awaits an additional prevention strategy, such as maternal immunization.

Methods

We performed a prospective, multicenter, case-control study of 33 mothers delivering neonates with early onset GBS infection (cases), and 99 age- and ethnicity-matched mothers colonized with the same capsular polysaccharide (CPS) types delivering healthy neonates (controls). Relative risk and absolute risk were calculated for early onset disease associated with concentrations of type Ia, III, or V CPS-specific antibody in maternal serum.

Results

For GBS types Ia and III, maternal CPS-specific antibody concentrations of ≥ 0.5 µg/mL were associated with a relative risk of approxim

SUBMITTER: Baker CJ 

PROVIDER: S-EPMC3923540 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature